Ibogaine analogs as therapeutics for neurological and psychiatric disorders
AssigneeThe Trustees of Columbia University in the City of New York
InventorsDalibor Sames, Vaclav Havel
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure: wherein R1 is wherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, or wherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site, or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.
Claims29
A composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:
- wherein R1 is
- wherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, or
- wherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site,
- or a pharmaceutically acceptable salt of the compound,
- wherein in the mixture the proportion of molecules having deuterium at the at least one of H1, H2, H3 H4 or H5 position is substantially greater than 0.0156% of molecules in the mixture.
-8. (canceled)
-15. (canceled)
A composition which comprises a carrier and a compound having the structure:
- wherein R1 is
- wherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, or
- wherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site,
- or a pharmaceutically acceptable salt of the compound.
-24. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-37. (canceled)
A method for systemic in vivo delivery of a first compound having the structure:
- to a subject, the method comprising administering to the subject a composition which comprises a carrier and a second compound having the structure:
- wherein R1 is
- wherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, or
- wherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site,
- or a pharmaceutically acceptable salt of the compound, so as to thereby deliver the first compound to the subject.
-43. (canceled)
Dependencies are inferred from the claim text.